These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 23155362)
1. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Lee YJ; Won AJ; Lee J; Jung JH; Yoon S; Lee BM; Kim HS Int J Med Sci; 2012; 9(10):881-93. PubMed ID: 23155362 [TBL] [Abstract][Full Text] [Related]
2. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700 [TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769 [TBL] [Abstract][Full Text] [Related]
4. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416 [TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267 [TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo. Yang B; Yu D; Liu J; Yang K; Wu G; Liu H Tumour Biol; 2015 Jul; 36(7):5051-61. PubMed ID: 25649979 [TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells. You BR; Han BR; Park WH Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148 [TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. Xu XD; Yang L; Zheng LY; Pan YY; Cao ZF; Zhang ZQ; Zhou QS; Yang B; Cao C BMC Cancer; 2014 May; 14():373. PubMed ID: 24886166 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells. Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787 [TBL] [Abstract][Full Text] [Related]
12. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Bellarosa D; Bressan A; Bigioni M; Parlani M; Maggi CA; Binaschi M Int J Oncol; 2012 Oct; 41(4):1486-94. PubMed ID: 22797667 [TBL] [Abstract][Full Text] [Related]
13. Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways. Lim JS; Kyung SY; Jeon Y; Kim IS; Kwak JH; Kim HS Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36633143 [No Abstract] [Full Text] [Related]
14. Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Wang J; Kim TH; Ahn MY; Lee J; Jung JH; Choi WS; Lee BM; Yoon KS; Yoon S; Kim HS Int J Oncol; 2012 Sep; 41(3):1101-9. PubMed ID: 22751989 [TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway. Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704 [TBL] [Abstract][Full Text] [Related]
16. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705 [TBL] [Abstract][Full Text] [Related]
17. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells. Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592 [TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
20. Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Kim S; Lee J; Oh SJ; Nam SJ; Lee JE Oncol Rep; 2015 Sep; 34(3):1613-9. PubMed ID: 26166014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]